ES2133271T3 - Receptores para factores de crecimiento de fibroblastos. - Google Patents

Receptores para factores de crecimiento de fibroblastos.

Info

Publication number
ES2133271T3
ES2133271T3 ES90911235T ES90911235T ES2133271T3 ES 2133271 T3 ES2133271 T3 ES 2133271T3 ES 90911235 T ES90911235 T ES 90911235T ES 90911235 T ES90911235 T ES 90911235T ES 2133271 T3 ES2133271 T3 ES 2133271T3
Authority
ES
Spain
Prior art keywords
growth factor
explosion
fibers
fgf
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90911235T
Other languages
English (en)
Inventor
Lewis T Williams
Daniel E Johnson
Pauline E Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California, San Diego
Original Assignee
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California, San Diego filed Critical University of California Berkeley
Application granted granted Critical
Publication of ES2133271T3 publication Critical patent/ES2133271T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

SE HA PURIFICADO UN RECEPTOR PARA EL FACTOR DE CRECIMIENTO POR EXPLOSION DE LAS FIBRAS (FGF) QUE INCLUYE UN RECEPTOR PARA EL FACTOR DE CRECIMIENTO POR EXPLOSION DE LAS FIBRAS. SE HAN IDENTIFICADO VARIAS FORMAS ENTRE LAS QUE CABE INCLUIR FORMAS SOLUBLES QUE NO TIENEN NINGUN SEGMENTO DE TRANSMEMBRANA. SE HAN AISLADO Y SECUENCIADO LAS SECUENCIAS DE ADN QUE CODIFICAN A LOS RECEPTORES PARA EL FACTOR DE CRECIMIENTO POR EXPLOSION DE FIBRAS DE LONGITUD TOTAL Y POLIPEPTIDOS QUE CONTIENEN UNA PARTE DE UN DOMINIO ENLAZADOR DE UN LIGANDO DEL FGF-R. ESTOS ADNS INCLUYEN ADNS QUE CODIFICAN UN FGF-R BASICO Y UN FGF-R HUMANO Y SON ENLAZADOS DE MANERA QUE SEAN CAPACES DE FUNCIONAR PARA CONTROLAR LAS SECUENCIAS Y EXTRESADOS EN UN CULTIVO DE UN HUESPED COMPATIBLE TRANSFORMADO, TRANSFECTADO O ELECTROACTIVADO POR UN VEHICULO DE CLONACION QUE CONTIENE LA SECUENCIA DE ADN. LA INVENCION TAMBIEN SE REFIERE A ANTICUERPOS PARA EL RECEPTOR, METODOS PARA SINTETIZAR LAS PROTEINAS DEL RECEPTOR PARA EL FACTOR DE CRECIMIENTO, METODOS PARA PROPORCIONAR ANALOGOS DE LOS RECEPTORES PARA EL FACTOR DE CRECIMIENTO POR EXPLOSION DE LAS FIBRAS. TAMBIEN SE DESCRIBEN LOS METODOS PARA EVALUAR LAS COMPOSICIONES QUE PROMUEVEN O INHIBEN LOS FACTORES DE CRECIMIENTO POR EXPLOSION DE LAS FIBRAS QUE SON AGONISTICOS O ANTAGONISTICOS A LOS RECEPTORES PARA EL FACTOR DE CRECIMIENTO POR EXPLOSION DE LAS FIBRAS. SE DESCRIBEN LOS USOS TERAPEUTICOS Y DE DIAGNOSTICO.
ES90911235T 1989-07-06 1990-07-06 Receptores para factores de crecimiento de fibroblastos. Expired - Lifetime ES2133271T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37700389A 1989-07-06 1989-07-06

Publications (1)

Publication Number Publication Date
ES2133271T3 true ES2133271T3 (es) 1999-09-16

Family

ID=23487374

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90911235T Expired - Lifetime ES2133271T3 (es) 1989-07-06 1990-07-06 Receptores para factores de crecimiento de fibroblastos.

Country Status (15)

Country Link
US (4) US6384191B1 (es)
EP (1) EP0481000B1 (es)
JP (1) JP3039802B2 (es)
KR (1) KR100235266B1 (es)
AT (1) ATE179862T1 (es)
AU (1) AU638734B2 (es)
CA (1) CA2063431C (es)
DE (1) DE69033109T2 (es)
DK (1) DK0481000T3 (es)
ES (1) ES2133271T3 (es)
FI (1) FI920027A7 (es)
HU (1) HU215581B (es)
NO (1) NO310032B1 (es)
SG (1) SG72657A1 (es)
WO (1) WO1991000916A2 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001466D0 (en) * 1990-01-23 1990-03-21 Erba Carlo Spa Extracellular form of the human fibroblast growth factor receptor
WO1991000916A2 (en) 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
JP2552942B2 (ja) * 1990-06-01 1996-11-13 三井東圧化学株式会社 ヒトｂーＦＧＦ受容体遺伝子
ATE243253T1 (de) * 1990-07-06 2003-07-15 Rhone Poulenc Rorer Internat H Rezeptoren der wachstumsfaktoren aus fibroblasten
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
IL100219A0 (en) * 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
DK0646182T3 (da) * 1992-06-18 1996-09-16 Whittier Inst Diabetes & Endoc Fremgangsmåde til påvisning af neoplastiske sygdomme
KR100335584B1 (ko) * 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6214795B1 (en) 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
WO1999055861A2 (en) * 1998-04-28 1999-11-04 Eisai Co., Ltd. Fibroblast growth factor mutein compositions and methods of use therefor
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20020192719A1 (en) * 1998-09-30 2002-12-19 Caliper Technologies Corp. Homogeneous assay methods
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
EE200100603A (et) * 1999-05-14 2003-02-17 Imclone Systems Incorporated Inimese refraktaarsete kasvajate ravi epidermaalse kasvufaktori retseptori antagonistidega
AU2001295002B2 (en) * 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
AU2002236477A1 (en) * 2000-11-21 2002-06-03 The Texas A & M University System Fgf-affinity chromatography
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003072126A2 (de) * 2002-02-28 2003-09-04 Switch Biotech Ag Verwendung eines fibroblastenwachstumsfaktor-bindeproteins zur behandlung und diagnose von diabetischen wundheilungsstörungen
DK1340507T3 (da) * 2002-02-28 2005-02-28 Switch Biotech Ag Anvendelse af et fibroblastvækstfaktor-bindingsprotein til behandling og diagnosticering af diabetiske sårhelingsforstyrrelser
CA2510715A1 (en) * 2002-12-20 2004-07-08 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
WO2005066211A2 (en) * 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
ES2387809T3 (es) * 2004-03-19 2012-10-02 Imclone Llc Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
EP2247615B1 (en) 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
SG193860A1 (en) 2008-06-04 2013-10-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
CN102171343B (zh) 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
NZ592009A (en) 2008-10-10 2012-11-30 Amgen Inc Fgf21 mutants and uses thereof
DK3290052T3 (da) 2008-11-07 2020-02-03 Galaxy Biotech Llc Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
ES2549769T3 (es) 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
JP2012530493A (ja) * 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド キメラポリペプチドおよびその使用
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
PT2498799T (pt) 2009-11-13 2016-11-04 Five Prime Therapeutics Inc Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2
MX2012006397A (es) * 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
US8435525B1 (en) 2010-04-16 2013-05-07 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
US9226960B2 (en) 2010-04-16 2016-01-05 Andrew B. Bush FGF modulation of in vivo antibody production and humoral immunity
CA2800311A1 (en) 2010-05-11 2011-11-17 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
MX349293B (es) 2010-11-15 2017-07-21 Five Prime Therapeutics Inc * Tratamiento de cancer con dosis elevadas de proteinas de fusion del receptor del factor de crecimiento de fibroblastos 1 (fgfr1) solubles.
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
WO2013074492A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. Methods of treating cancer
MX374785B (es) 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
US10373702B2 (en) * 2014-03-27 2019-08-06 Massachusetts Institute Of Technology Water-soluble trans-membrane proteins and methods for the preparation and use thereof
EP3197474B1 (en) * 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
US10844392B2 (en) 2015-06-05 2020-11-24 Ibio, Inc. Materials and methods for producing endostatin fusion polypeptides in plant cells
SG10201913538VA (en) 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
DK3624837T3 (da) 2017-05-16 2025-09-29 Five Prime Therapeutics Inc Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling
TW202229343A (zh) 2020-08-21 2022-08-01 美商健臻公司 Fgfr3抗體及使用方法
JP2024534053A (ja) 2021-08-25 2024-09-18 アイバイオ， インク． 抗ｃｄ２５抗体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4785079A (en) * 1984-11-09 1988-11-15 The Salk Institute For Biological Studies Isolation of fibroblast growth factor
US4668476A (en) * 1984-03-23 1987-05-26 Applied Biosystems, Inc. Automated polypeptide synthesis apparatus
US4761371A (en) 1985-02-12 1988-08-02 Genentech, Inc. Insulin receptor
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5057417A (en) * 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US4968607A (en) * 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5081228A (en) * 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
SE8804164A0 (sv) * 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
WO1991000916A2 (en) 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
US5229501A (en) * 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
US6022741A (en) * 1997-03-13 2000-02-08 University Of North Carolina At Chapel Hill Regulatory genetic DNA that regulates the Class II transactivator (CIITA)

Also Published As

Publication number Publication date
KR100235266B1 (en) 1999-12-15
EP0481000B1 (en) 1999-05-12
US5707632A (en) 1998-01-13
DE69033109T2 (de) 1999-11-18
HU215581B (hu) 1999-01-28
SG72657A1 (en) 2000-05-23
ATE179862T1 (de) 1999-05-15
NO920060D0 (no) 1992-01-03
HUT61052A (en) 1992-11-30
HU906195D0 (en) 1992-06-29
NO310032B1 (no) 2001-05-07
WO1991000916A2 (en) 1991-01-24
JP3039802B2 (ja) 2000-05-08
AU6077990A (en) 1991-02-06
CA2063431C (en) 2002-10-29
CA2063431A1 (en) 1991-01-07
US6350593B1 (en) 2002-02-26
DE69033109D1 (de) 1999-06-17
AU638734B2 (en) 1993-07-08
NO920060L (no) 1992-03-02
FI920027A0 (fi) 1992-01-03
FI920027A7 (fi) 1992-01-03
DK0481000T3 (da) 1999-11-15
EP0481000A1 (en) 1992-04-22
EP0481000A4 (en) 1992-10-21
JPH04506604A (ja) 1992-11-19
US6384191B1 (en) 2002-05-07
US6355440B1 (en) 2002-03-12
WO1991000916A3 (en) 1991-10-17

Similar Documents

Publication Publication Date Title
ES2149772T3 (es) Receptores humanos pf4a y su utilizacion.
DK0481000T3 (da) Receptorer for fibroblastvækstfaktorer
AR010752A1 (es) COMPUESTOS QUE SE ENLAZAN A Y ACTIVAN UN RECEPTOR DE LA TROMBOPOYETINA; COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, SU USO PARA LA PREPARACION DE MEDICAMENTOS, Y PROCESO PARA PREPARAR DICHA COMPOSICIoN.
GT199700141A (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas.
GT199800083A (es) Agonistas de prostaglandinas.
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
CR9570A (es) Formulaciones y usos del peptido receptor de eritropoyetina
AR003634A1 (es) Conjugados de ligando de afinidad-matriz, metodos para su preparacion, ligandos de afinidad, metodos para unir ligandos, y uso de dichos conjugados
DE3853328D1 (de) Subtilisin-analoge.
ES2038571T1 (es) Procedimiento de preparacion de anticuerpos monoclonales especificos de las interleucinas 1alfa y 1beta.
ES2154167A1 (es) Aminoderivados ciclicos antagonistas del receptor ccr-3.
MX9204685A (es) Secuencia de adn que codifica una proteina superficial externa (ospa) o derivado de la misma composicion de vacuna qe comprende tal proteina.
MX337162B (es) Anticuerpos contra el receptor del factor de crecimiento similar a insulina.
GT199800106A (es) Azetidinas.
ES2094907T3 (es) Secuencias de adn que codifican para caracteristicas de virulencia de -s(streptococcus suis) y partes del mismo, polipeptidos y anticuerpos derivados de este y su uso para la diagnosis y la proteccion contra la infeccion por -s(s. suis) en mamiferos, incluyendo el ser humano.
ES2534224T3 (es) Receptor de células T específico para el antígeno tumoral de Wilms
ES2047014T3 (es) Procedimiento para preparar un catalizador basado en plata y procedimiento para epoxidar olefinas superiores.
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
ES2069099T3 (es) Vacuna recombinante para la pleuroneumonia porcina.
DK0506923T3 (da) Et collagenbindende protein samt fremstilling deraf
ES2159306T3 (es) Vacuna contra coccidiosis en pollos.
AR006150A1 (es) Proteina de via complementaria natural modificada capaz de formar una convertasa c3 resistente a la regulacion descendente, secuencias de adn quecodifican dicha proteina, usos de dicha proteina y composiciones que la contienen
ES2156889T3 (es) Compuestos biciclicos antagonistas de receptores de aminoacidos excitativos.
ES2139667T3 (es) Peptidos sinteticos para el tratamiento de la miastenia gravis.
ES2193401T3 (es) Peptidos aptos como agente de diagnostico y agente terapeutico para las enfermedades autoinmunitarias.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 481000

Country of ref document: ES